Products for Research Use Only
RegisterLogin

RET-IN-19

CAT: 0804-HY-151377Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-151377Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1].
CAS Number
2484919-71-1
UNSPSC
12352005
Target
Aurora Kinase; c-Fms; EGFR; MAP4K; RET
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ret-in-19.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=NOC(C(C)(C)C)=C1)CC2=CC=C(NC3=C4C(NC(C5=CC=C(S(=O)(C)=O)C=C5)=C4)=NC=N3)C=C2
Molecular Formula
C28H28N6O4S
Molecular Weight
544.62
References & Citations
[1]Lakkaniga NR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15;206:112691.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Aurora A; Aurora B; EGFR/ErbB1/HER1; MAP4K4/HGK

Related Products

CatalogName
HY-148742-01RET-IN-21
HY-112950RET-IN-1
HY-145024RET-IN-6
HY-153676-01RET-IN-23
HY-133553-01RET-IN-3
HY-145023RET-IN-5
HY-178786RET-IN-31
HY-147563RET-IN-17
HY-144422RET-IN-15
HY-149099RET-IN-22

Alternative Products

CatalogName
GTR19184777-01RET-IN-19
R1701-17RET protein (RET)
V8277-100UGRET Antibody / c-RET
V8276-100UGC-RET Antibody / RET
030598RET (ret proto-oncogene)
332425-01Ret

Popular Products